Merck (our supposed partner) are always happy to takeover...

Merck (our supposed partner) are always happy to takeover flailing Australian companies in early stage development (see below example in 2018) and yet Starpharma boast / tout to the market in reporting that they have had such success in their phase 2 DEP® trials and yet we can't even attract a DEP® (or ADC) license deal from Merck let alone an opportunistic takeover bid...... but hey some on here continually claim "the science is so good" ??? Not really looking like it at this stage






https://www.fiercebiotech.com/biotech/merck-inks-394m-takeover-oncolytic-virus-play-viralytics

Merck inks $394M takeover of oncolytic virus play Viralytics


Merck is set to pay $394 million to acquire Viralytics. The takeover will give Merck control of an oncolytic immunotherapy that Viralytics is testing in combination with Keytruda in early-phase trials.


Sydney-based Viralytics’ most advanced candidate is Cavatak, a common cold RNA virus. Viralytics selected the nongenetically altered virus on the strength of its ability to target ICAM-1 and infect a variety of cancer cells. Once inside the cells, the virus starts wiping out the tumor through oncolytic and immunotherapeutic activity. That mechanism chimes with Merck’s strategy.